Literature DB >> 31549966

Proactive steps to optimize the management of polycythemia vera and myelofibrosis.

Ruben A Mesa1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31549966      PMCID： PMC8895346     

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  9 in total

1.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

2.  Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.

Authors:  Claire N Harrison; Alessandro M Vannucchi; Uwe Platzbecker; Francisco Cervantes; Vikas Gupta; David Lavie; Francesco Passamonti; Elliott F Winton; Hua Dong; Jun Kawashima; Julia D Maltzman; Jean-Jacques Kiladjian; Srdan Verstovsek
Journal:  Lancet Haematol       Date:  2017-12-20       Impact factor: 18.959

3.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

4.  Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael W N Deininger; Carole B Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth O Hexner; Roger M Lyons; Azra Raza; Kris Vaddi; William Sun; Wei Peng; Victor Sandor; Hagop Kantarjian
Journal:  Haematologica       Date:  2015-01-23       Impact factor: 9.941

5.  Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.

Authors:  John Mascarenhas; Ronald Hoffman; Moshe Talpaz; Aaron T Gerds; Brady Stein; Vikas Gupta; Anita Szoke; Mark Drummond; Alexander Pristupa; Tanya Granston; Robert Daly; Suliman Al-Fayoumi; Jennifer A Callahan; Jack W Singer; Jason Gotlib; Catriona Jamieson; Claire Harrison; Ruben Mesa; Srdan Verstovsek
Journal:  JAMA Oncol       Date:  2018-05-01       Impact factor: 31.777

6.  Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

Authors:  Claire N Harrison; Nicolaas Schaap; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Ramon V Tiu; Pierre Zachee; Eric Jourdan; Elliott Winton; Richard T Silver; Harry C Schouten; Francesco Passamonti; Sonja Zweegman; Moshe Talpaz; Joanne Lager; Zhenming Shun; Ruben A Mesa
Journal:  Lancet Haematol       Date:  2017-06-08       Impact factor: 18.959

7.  Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.

Authors:  Martin Griesshammer; Guray Saydam; Francesca Palandri; Giulia Benevolo; Miklos Egyed; Jeannie Callum; Timothy Devos; Serdar Sivgin; Paola Guglielmelli; Caroline Bensasson; Mahmudul Khan; Julian Perez Ronco; Francesco Passamonti
Journal:  Ann Hematol       Date:  2018-05-27       Impact factor: 3.673

8.  Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Authors:  C N Harrison; A M Vannucchi; J-J Kiladjian; H K Al-Ali; H Gisslinger; L Knoops; F Cervantes; M M Jones; K Sun; M McQuitty; V Stalbovskaya; P Gopalakrishna; T Barbui
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528

9.  Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.

Authors:  Srdan Verstovsek; Jason Gotlib; Ruben A Mesa; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Francisco Cervantes; Claire N Harrison; Ronald Paquette; William Sun; Ahmad Naim; Peter Langmuir; Tuochuan Dong; Prashanth Gopalakrishna; Vikas Gupta
Journal:  J Hematol Oncol       Date:  2017-09-29       Impact factor: 17.388
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.